Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VXCO-100 in Healthy Adults in the United States

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VXCO-100 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Vaccine Company

Most Recent Events

10 Dec 2024 Status changed from active, no longer recruiting to completed.
10 Jan 2024 Planned number of patients changed from 150 to 121.
10 Jan 2024 The protocol has been amended to change treatment arm and Time frame of assessing serious adverse events (SAEs) including suspected unexpected serious adverse reactions changed to 304 days with change in patient population.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com